Finally, understanding if AhR and RelB levels in the lung are inherently low (i. e. not due to disease progression) could also form the basis for anti-inflammatory therapies targeting an AhR-RelB axis in COPD, a disease with few options to treat the underlying inflammation that may drive disease progression. The gene discussed is AHR; the disease is chronic obstructive pulmonary disease.